2023
Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial
Deng Y, Polley E, Wallach J, Herrin J, Ross J, McCoy R. Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial. BMJ Medicine 2023, 2: e000419. PMID: 37577025, PMCID: PMC10414064, DOI: 10.1136/bmjmed-2022-000419.Peer-Reviewed Original ResearchYear cumulative incidence rateCumulative incidence rateType 2 diabetesLiraglutide armMetabolic failureSitagliptin armGlycaemic controlInsulin glargineMedian timeIncidence rateComparative effectivenessCox proportional hazards regressionPropensity scoreTarget trialsInsulin glargine armProportional hazards regressionOptumLabs Data WarehouseTarget trial emulationStatistical analysis planMetformin monotherapyMacrovascular complicationsMicrovascular outcomesStudy drugStudy armsTrial emulation
2011
Improvements in Door-to-Balloon Time in the United States, 2005 to 2010
Krumholz HM, Herrin J, Miller LE, Drye EE, Ling SM, Han LF, Rapp MT, Bradley EH, Nallamothu BK, Nsa W, Bratzler DW, Curtis JP. Improvements in Door-to-Balloon Time in the United States, 2005 to 2010. Circulation 2011, 124: 1038-1045. PMID: 21859971, PMCID: PMC3598634, DOI: 10.1161/circulationaha.111.044107.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionBalloon timeCoronary interventionMedian timeST-segment elevation myocardial infarctionHigher median timeCharacteristics of patientsPercentage of patientsTimeliness of treatmentYears of ageRegistry studyMyocardial infarctionInpatient measuresPatientsHospital groupMedicaid ServicesCalendar yearInterventionMinutesMedianGroupYearsPercentageInfarction